2Colucci RD, Swanton RE, Thomas GB, et al.Relative vari- ability in bioavailability of oral controlled-release formu- lations of oxycodone and morphine[J].Am J Ther, 2001, 8 (4):231.
3Hermos JA, Young MM, Gagnon DR, et al.Characteriza- tions of long-term oxycodone/acetaminophen prescrip- tions in veteran patients[J].Arch Intern Med, 2004, 164 (21):2361.
4Caraceni A, Hanks G, Kaasa S, et a/.Use of opioid analge- sics in the treatment of cancer pain: evidence-based rec- ommendations from the EAPC[J]. Lancet Oncol, 2012,13 (2):58.
5美国国立综合癌症网络.成人癌痛临床实践指南:中国版[S].2010,11.
6Mercadante S. The use of rapid onset opioids for break- through cancer pain: the challenge of its dosing[J]. Crit Rev Oncol Hematol, 2011,80 (3) : 460.
7Wiffen P J, Wee B, Moore RA. Oral morphine for cancer pain[J]. Cochrane Database Syst Rev, 2013,7 : 1.
8Perrino P J, Colucci SV, Apseloff G, et al. Pharmacoki- netics, tolerability, and safety of intranasal administra- tion of reformulated OxyContin: tablets compared with original OxyContin: tablets in healthy adults[J]. Clin Drug lnvestig, 2013,33(6) :441.
